Search

Pfizer

Avatud

SektorTervishoid

27.79 0.04

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

27.57

Max

27.94

Põhinäitajad

By Trading Economics

Sissetulek

-2.9B

-238M

Müük

583M

15B

P/E

Sektori keskmine

37.434

56.597

Aktsiakasum

0.77

Dividenditootlus

5.97

Kasumimarginaal

-1.583

Töötajad

75,000

EBITDA

-3.8B

1.2B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+2.41% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

5.97%

2.18%

Järgmine tulemuste avaldamine

3. nov 2026

Järgmine aktsia dividendi kuupäev (ex-date)

6. nov 2026

Turustatistika

By TradingEconomics

Turukapital

19B

162B

Eelmine avamishind

27.75

Eelmine sulgemishind

27.79

Uudiste sentiment

By Acuity

48%

52%

127 / 339 Pingereas Healthcare

Pfizer Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. sept 2026, 20:08 UTC

News
Social Media

Pfizer shares are lower as the company announces a webcast featuring CEO Albert Bourla at the Morgan Stanley Healthcare Conference scheduled for September 2026.

4. sept 2026, 23:05 UTC

Pfizer Inc shares are lower in after-market hours, reflecting a slight decline since Friday's close amid mixed economic signals affecting market sentiment.

3. sept 2026, 23:01 UTC

Pfizer Inc. shares are lower in after-market hours, following a weak trading session and amid broader market softness from recent economic data on jobless claims.

2. sept 2026, 23:06 UTC

Pfizer Inc. shares are lower in after-market hours, amid a weaker ADP payrolls report signaling potential labor market weakness affecting future Federal Reserve policy.

1. sept 2026, 20:09 UTC

News

Pfizer Inc shares reached a 22-month high of $28.86 today, driven by a significant upward trend in the Pharmaceuticals sub-sector amid overall market gains.

31. aug 2026, 23:06 UTC

Pfizer Inc shares rose in after-hours trading, holding above the 20-day moving average and near the upper end of their one-month range.

28. aug 2026, 23:01 UTC

Pfizer Inc. shares are lower in after-market trading, continuing a trend from the previous three sessions. No specific news was identified to explain the decline.

27. aug 2026, 23:02 UTC

Social Media
News

Pfizer and BioNTech received FDA approval for their XFG-adapted COVID-19 vaccine, COMIRNATY XFG, boosting shares in after-market trading.

26. aug 2026, 23:06 UTC

Pfizer Inc shares are lower in after-market hours amid notable volatility. Broader market weakness and a stronger U.S. Dollar Index contributed to the decline.

25. aug 2026, 23:06 UTC

Pfizer Inc. shares are lower in after-market trading, reflecting weaker sentiment amid broader market declines linked to falling crude oil prices.

24. aug 2026, 19:36 UTC

Pfizer Inc. shares are lower today, continuing a decline since Friday's close. The stock remains above its 20-day moving average.

21. aug 2026, 23:01 UTC

Pfizer Inc shares are lower in after-market trading, reflecting a downward trend amid broader market volatility related to inflation and government debt concerns.

20. aug 2026, 19:41 UTC

Pfizer Inc's shares are lower today amid a broader downturn in the Pharmaceuticals sub-sector, marking a shift from recent gains.

19. aug 2026, 23:51 UTC

Pfizer Inc shares are lower in after-market hours, reversing gains from three consecutive sessions. No specific news was identified to explain the price action.

18. aug 2026, 19:16 UTC

Social Media
Event

Pfizer reported second-quarter adjusted EPS of $0.77, exceeding estimates, and raised its sales outlook for fiscal year 2026, with shares trading higher.

17. aug 2026, 23:36 UTC

Event

Pfizer Inc shares are lower in after-market hours following the announcement of Xtandi's new indication for prostate cancer treatment. The broader market also declined.

14. aug 2026, 23:51 UTC

Pfizer Inc. shares are higher in after-market hours amid broader economic concerns following a reported decline in U.S. retail sales for July.

13. aug 2026, 23:16 UTC

Pfizer Inc shares are lower in after-market hours following a decline from earlier gains. No specific news was identified to explain the movement.

12. aug 2026, 23:02 UTC

Social Media
News

Pfizer shares rose after Chairman Albert Bourla bought 38,000 shares at $26.34, totaling about $1 million, signaling confidence in the company's prospects.

11. aug 2026, 19:26 UTC

News

Pfizer Inc. shares are lower amid a $44 million settlement over its Chantix drug, which allegedly contained a cancer-linked substance.

10. aug 2026, 23:01 UTC

Pfizer Inc. shares are lower in after-market hours, continuing a decline since Monday's close amid rising Treasury yields and inflation concerns.

8. aug 2026, 00:02 UTC

Pfizer Inc shares are lower in after-market hours with no specific news identified. Broader market concerns about interest rate hikes continue to influence sentiment.

7. aug 2026, 23:01 UTC

Pfizer Inc shares are lower in after-market hours, reaching a session low earlier. No specific news was identified to explain the decline.

6. aug 2026, 23:51 UTC

Pfizer Inc shares are lower in after-market hours. The decline follows increased crude oil prices and a strengthening U.S. dollar, contributing to market volatility.

5. aug 2026, 23:02 UTC

Pfizer Inc shares are modestly higher in after-market hours, reaching a session high before pulling back slightly. No specific news was identified for the movement.

4. aug 2026, 23:21 UTC

Pfizer Inc shares are lower in after-market hours, with no specific news identified for the decline. Broader market sentiment remains positive amid falling crude oil prices.

3. aug 2026, 23:46 UTC

Social Media

Pfizer Inc shares are higher in after-market trading ahead of earnings. The stock remains above its 20-day moving average, reflecting positive market sentiment.

31. juuli 2026, 23:06 UTC

Pfizer Inc shares are higher in after-market hours, reflecting slight gains since Friday's close. The stock remains near the upper end of its one-month range.

30. juuli 2026, 23:26 UTC

Event

Pfizer shares are higher in after-market trading following Phase 3 trial results for LITFULO in nonsegmental vitiligo, despite three prior sessions of lower closes.

29. juuli 2026, 23:16 UTC

News

Pfizer and BioNTech received European Commission approval for their XFG-adapted COVID-19 vaccine, valid across all EU member states. Shares are trading roughly flat after-market.

Võrdlus sarnastega

Hinnamuutus

Pfizer Prognoos

Hinnasiht

By TipRanks

2.41% tõus

12 kuu keskmine prognoos

Keskmine 28.46 USD  2.41%

Kõrge 35.75 USD

Madal 25 USD

Põhineb 21 Wall Streeti analüütiku instrumendi Pfizer 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

21 ratings

7

Osta

13

Hoia

1

Müü

Sentiment

By Acuity

127 / 339 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat